BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 17503040)

  • 21. Dendritic cells as vectors for immunotherapy of cancer.
    Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK
    Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DC-based cancer vaccines: lessons from clinical trials.
    Brody JD; Engleman EG
    Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
    [No Abstract]   [Full Text] [Related]  

  • 23. Dendritic cell-based immunotherapy of malignant gliomas.
    Parajuli P; Sloan AE
    Cancer Invest; 2004; 22(3):405-16. PubMed ID: 15493362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies.
    Kajihara M; Takakura K; Ohkusa T; Koido S
    Immunotherapy; 2015; 7(10):1111-22. PubMed ID: 26507578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cell biology and its role in tumor immunotherapy.
    Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
    J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.
    Burdin N; Moingeon P
    Cell Biol Toxicol; 2001; 17(2):67-75. PubMed ID: 11499697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
    Bhargava A; Mishra D; Banerjee S; Mishra PK
    Immunotherapy; 2012 Jul; 4(7):703-18. PubMed ID: 22853757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cells in cancer vaccines.
    Brossart P; Wirths S; Brugger W; Kanz L
    Exp Hematol; 2001 Nov; 29(11):1247-55. PubMed ID: 11698120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
    Rolinski J; Hus I
    J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic Cell-Based Immunotherapy in Lung Cancer.
    Stevens D; Ingels J; Van Lint S; Vandekerckhove B; Vermaelen K
    Front Immunol; 2020; 11():620374. PubMed ID: 33679709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing dendritic cell-based immunotherapy for cancer.
    Zhong H; Shurin MR; Han B
    Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Building on dendritic cell subsets to improve cancer vaccines.
    Palucka K; Ueno H; Zurawski G; Fay J; Banchereau J
    Curr Opin Immunol; 2010 Apr; 22(2):258-63. PubMed ID: 20226644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cell-based immunotherapy for the treatment of hematological malignancies.
    Büchler T; Michalek J; Kovarova L; Musilova R; Hajek R
    Hematology; 2003 Apr; 8(2):97-104. PubMed ID: 12745659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
    Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
    Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico prediction of cancer immunogens: current state of the art.
    Doytchinova IA; Flower DR
    BMC Immunol; 2018 Mar; 19(1):11. PubMed ID: 29544447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
    Tacken PJ; de Vries IJ; Torensma R; Figdor CG
    Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy.
    Cannon MJ; Block MS; Morehead LC; Knutson KL
    Immunotherapy; 2019 Feb; 11(2):75-79. PubMed ID: 30730268
    [No Abstract]   [Full Text] [Related]  

  • 39. Dendritic cell vaccination and immune monitoring.
    Aarntzen EH; Figdor CG; Adema GJ; Punt CJ; de Vries IJ
    Cancer Immunol Immunother; 2008 Oct; 57(10):1559-68. PubMed ID: 18618110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Q&A: Evidence presenter. Interview by Marian Turner.
    Palucka K
    Nature; 2013 Dec; 504(7480):S9. PubMed ID: 24352364
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.